Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …

Hyperphosphatemia, which is nearly universal in kidney failure, is accompanied by low
serum levels of vitamin D and hypocalcemia. Without treatment, severe secondary …

Masafumi Fukagawa, 1 Keitaro Yokoyama, 1 Fumihiko Koiwa, 1 Masatomo Taniguchi, 1
Tetsuo Shoji, 1 Junichiro James Kazama, 1 Hirotaka Komaba, 1 Ryoichi Ando, 1 Takatoshi …

Serum calcium concentration is the main determinant of parathyroid hormone (PTH) release.
Defect in the activation of vitamin D in the kidneys due to chronic kidney disease (CKD) …

Hyperphosphatemia has been associated with higher mortality risk in CKD 5 patients
receiving dialysis. Here, we determined the association between the use of single and …

Secondary hyperparathyroidism is a frequently encountered problem in the management of
patients with chronic kidney disease (CKD). Its pathophysiology is mainly due to …

Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …

Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with
increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate …

Background. In chronic kidney disease (CKD) patients, the ability to excrete a phosphate
load is impaired. Compensatory increase in parathyroid hormone (PTH) and fibroblast …

Phosphate binders include calcium acetate or carbonate, sevelamer hydrochloride or
carbonate, magnesium and lanthanum carbonate, and aluminum carbonate or hydroxide …